Radiopharma
Sanofi Challenges Novartis’ Dominance with Clinically Meaningful Pancreatic Tumor Data from AlphaMedix Phase II Trial
Sanofi; Novartis; radiopharma; AlphaMedix; Orano Med; gastroenteropancreatic neuroendocrine tumors; GEP-NETs; radioligand therapy; Phase II clinical trial; progression-free survival; overall survival; safety profile
Nimble radiopharma biotech Actithera secures $75M Series A to enter the clinic
Actithera; radiopharma; Series A; biotech funding; clinic entry; Andreas Goutopoulos; startup financing
Telix Pharmaceuticals Raises $400M in Bond Sale Amid IPO Uncertainty
Telix Pharmaceuticals, Bond Sale, IPO, Radiopharma, Funding